Enterohemorrhagic Escherichia coli

Current Opinion in Microbiology

Volumn 1, Issue 1, 1998, Pages 103-108

  Kaper, James B ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI;

BACTERIAL TOXIN; VEROTOXIN 1;

ANIMAL; CHILD; ENTEROBACTER INFECTION; EPIDEMIC; ESCHERICHIA COLI; FEMALE; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VIRULENCE;

ANIMALS; BACTERIAL TOXINS; CHILD; DISEASE OUTBREAKS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; SHIGA-LIKE TOXIN I; SIGNAL TRANSDUCTION; VIRULENCE;

EID: 0031987893     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(98)80149-5     Document Type: Article

References (51)

1. Nataro JP, Kaper JB: Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998, 11:in press. This comprehensive review covers all aspects of pathogenesis, epidemiology, detection, and treatment for all six classes of diarrheagenic E. coli. Many primary references that cannot be included in the present review due to space limitation will be found in this review.
2. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT: Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 1992, 180:65-94.
3. Lingwood CA: Role of verotoxin receptors in pathogenesis. Trends Microbiol 1996, 4:147-153. An extensive review of the glycolipid receptors for Shiga toxin that includes the structure of the receptor, the receptor-binding site of Shiga toxin, intra-cellular transport of the toxin, and signal transduction induced by the toxin.
4. Sandvig K, Van Deurs B: Endocytosis and intracellular sorting of ricin and Shiga toxin. FEBS Lett 1994, 346:99-102.
5. Armstrong GD, Rowe PC, Goodyer P, Orrbine E, Klassen TP, Wells G, Mackenzie A, Lior H, Blanchard C, Auclair F et al.: A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis 1995, 171:1042-1045.
6. Acheson DWK, Moore R, Debreucker S, Lincicome LL, Jacewicz M, Skutelsky E, Keusch GT: Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect Immun 1996, 64:3294-3300. This paper examines an aspect of pathogenesis that has received little attention, namely, how Shiga toxin (Stx) translocates from the intestine to the bloodstream. The authors show that biologically active Stx1 can move across intact polarized intestinal epithelial cells without apparent cellular damage, probably via a transcellular pathway, perhaps through nonspecific endocytosis. Much more research is needed on this topic but these authors make a good start in studying this process.
7. Tesh VL, Ramegowda B, Samuel JE: Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun 1994, 62:5085-5094.
8. Louise CB, Obrig TG: Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1β, and tumor necrosis factor alpha on human vascular endothelial cell in vivo. Infect Immun 1991, 59:4173-4179.
9. Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG: Shiga toxin-associated hemolytic uremic syndrome: interleukin-1β enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993, 61:3886-3891.
10. Van de Kar NCAJ, Monnens LAH, Karmali MA, Hinsbergh VWM: Tumor necrosis factor and interleukin-1 induce expression of the verotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992, 80:2755-2764.
11. Karpman D, Connell H, Svensson M, Scheutz F, Alm P, Svanborg C: The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J Infect Dis 1997, 175:611-620. This work is notable because it reproduces nearly all symptoms of the disease, including gastrointestinal (although not bloody diarrhea), neurological, and glomerular symptoms in a single, orally inoculated convenient animal model, a feat which other animal models have had difficulty achieving. This model also produced bacteremia in many animals, in contrast to the usual absence of bacteremia in human disease. This work uses genetically defined mouse strains to show that lipopolysaccharide is important for disease development.
12. Griffin PM: Escherichia coli O157:H7 and other enterohemorrhagic Escherichia coli. In Infections of the Gastrointestinal Tract. Edited by Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL New York: Raven Press; 1995:739-761.
13. Louise CB, Obrig TG: Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis 1995, 172:1397-1401.
14. 50 in mice. This result is particularly noteworthy because it is seen with a non-O157:H7 strain that lacks the LEE pathogenicity island and the intimin intestinal colonization factor. The activatable toxin may help explain why such strains can cause disease, i.e. the more active toxin may help compensate for the lack of the LEE and intimin. Another lesson to be learned from this study is the importance of keeping the actual in vivo disease conditions in mind when studying pathogenesis, i.e. the activity of the toxin should be examined in the presence of intestinal mucus rather than only as a highly purifed preparation in isolation.
15. Donnenberg MS, Kaper JB, Finlay BB: Interactions between enteropathogenic Escherichia coli and host epithelial cells. Trends Microbiol 1997, 5:109-114.
16. Ismaili A, Philpott DJ, Dytoc MT, Sherman PM: Signal transduction responses following adhesion of verocytotoxin-producing Escherichia coli.. Infect Immun 1995, 63:3316-3326.
17. Jung HC, Eckmann L, Yang S, Panja A, Fierer J, Morzycka-Wroblewska E, Kagnoff MF: A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995, 95:55-65.
18. Elliott E, Li Z, Bell C, Stiel D, Buret A, Wallace J, Brzuszczak I, O'Loughlin E: Modulation of host response to Escherichia coli O157:H7 infection by anti-CD18 antibody in rabbits. Gastroenterology 1994, 106:1554-1561.
19. Jerse AE, Yu J, Tall BD, Kaper JB: A gentic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc Natl Acad Sci USA 1990, 87:7839-7843.
20. Tzipori S, Gunzer F, Donnenberg MS, Demontigny L, Kaper JB, Donohue-Rolfe A: The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect Immun 1995, 63:3621-3627.
21. Donnenberg MS, Tacket CO, James SP, Losonsky G, Nataro JP. Wasserman SS, Kaper JB, Levine MM: Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest 1993, 92:1412-1417.
22. Mckee ML, Melton-Celsa AR, Moxley RA, Francis DH, O'Brien AD: Enterohemorrhagic Escherichia coli O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells. Infect Immun 1995, 63:3739-3744.
23. Agin TS, Wolf MK: Identification of a family of intimins common to Escherichia coli causing attaching-effacing lesions in rabbits, humans, and swine. Infect Immun 1997, 65:320-326. This study combines previously published sequences along with new data to show the existence of a family of intimin proteins with at least three different groups or subfamilies. Interestingly, sequences from some human isolates are closer to intimins from animal isolates than to other human isolates.
24. Rosenshine I, Ruschkowski S, Stein M, Reinscheid D, Mills SD, Finlay BB: A pathogenic bacterium triggers epithelial signals to form a functional bacterial receptor that mediates actin pseudopod formation. EMBO J 1996, 15:2613-2624.
25. 1 integrins. J Biol Chem 1996, 271:20359-20364.
26. Jarvis KG, Kaper JB: Secretion of extracellular proteins by enterohemorrhagic Escherichia coli via a putative type III secretion system. Infect Immun 1996, 64:4826-2829. The existence of a type III secretion system for enterohemorrhagic E. coli of the O157:H7 and O26:H11 serotypes is demonstrated in this paper. Type III secretion systems have been shown to be crucial in presenting virulence factors to host cells in a variety of Gram-negative pathogens. This study also shows that proteins secreted by the type III system are expressed in vivo as strong antibody responses against them are seen in serum from patients with hemolytic uremic syndrome.
27. Jarvis KG, Girón JA, Jerse AE, McDaniel TK, Donnenberg MS, Kaper JB: Enteropathogenic Escherichia coli contains a specialized secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. Proc Natl Acad Sci USA 1995, 92:7996-8000.
28. Ebel F, Deibel C, Kresse AU, Guzman CA, Chakraborty T: Temperature- and medium-dependent secretion of proteins by Shiga toxin-producing Escherichia coli. Infect Immun 1996, 64:4472-4479.
29. Kenny B, Lai L, Finlay BB, Donnenberg MS: EspA, a protein secreted by enteropathogenic Escherichia coli, is required to induce signals in epithelial cells. Mol Microbiol 1996, 20:313-324.
30. Foubister V, Rosenshine I, Donnenberg MS, Finlay BB: The eaeB gene of enteropathogenic Escherichia coli (EPEC) is necessary for signal transduction in epithelial cells. Infect Immun 1994, 62:3038-3040.
31. Lai L-C, Wainwright LA, Stone KD, Donnenberg MS: A third secreted protein that is encoded by the enteropathogenic Escherichia coli pathogenicity island is required for transduction of signals and for attaching and effacing activities in host cells. Infect Immun 1997, 65:2211-2217.
32. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB: A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci USA 1995, 92:1664-1668.
33. McDaniel TK, Kaper JB: A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype on E. coli K-12. Mol Microbiol 1997, 23:399-407. This work demonstrates that the LEE pathogenicity island is not only necessary for producing the attaching and effacing histopathology due to enteropathogenic E. coli, it is sufficient when cloned into K-12 or normal flora E. coli. This is the first example of a pathogenicity island from an enteric pathogen that can reproduce the pathognomic histopathology when cloned into E coli K-12.
34. Wieler LH, McDaniel TK, Whittam TS, Kaper JB: Insertion site of the locus of enterocyte effacement in enteropathogenic and enterohemorrhagic Escherichia coli differs in relation to the clonal phylogeny of the strains. FEMS Microbiol Lett 1997, in press.
35. Schmidt H, Kernbach C, Karch H: Analysis of the EHEC hly operon and its location in the physical map of the large plasmid of enterohaemorrhagic Escherichia coli O157:H7. Microbiology 1996, 142:907-914.
36. Brunder W, Schmidt H, Karch H: EspP, a novel extracellular serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves human coagulation factor V. Mol Microbiol 1997, 24:767-778.
37. Schmidt H, Henkel B, Karch H: A gene cluster closely related to type II secretion pathway operons of Gram-negative bacteria is located on a large plasmid of enterohemorrhagic Escherichia coli O157 strains. FEMS Microbiol Lett 1997, 148:265-272.
38. Schmidt H, Beutin L, Karch H: Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933. Infect Immun 1995, 63:1055-1061.
39. Bauer ME, Welch RA: Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7. Infect Immun 1996, 64:167-175.
40. Schmidt H, Karch H: Enterohemolytic phenotypes and genotypes of Shiga toxin-producing Escherichia coli O111 strains from patients with diarrhea and hemolytic uremic syndrome. J Clin Microbiol 1996, 34:2364-2367.
41. Torres AG, Payne SM: Haem iron-transport system in enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol 1997, 23:825-833.
42. Johnson RP, Clarke RC, Wilson JB, Read SC, Rahn K, Renwick SA, Sandhu KA, Alves D, Karmali MA, Lior H et al.: Growing concerns and recent outbreaks involving non-O157:H7 serotypes of verotoxigenic Escherichia coli. J Food Protect 1996, 59:1112-1122. This very comprehensive article reviews all aspects of non-O157:H7 enterohemorrhagic E. coli serotypes. The distribution of these serotypes in humans, animals, and foods is reviewed and the occurrence of potential virulence factors in these strains is discussed. Very useful tables summarizing the serotypes specifically associated with human disease and the reported outbreaks due to these serotypes are given. It is unfortunate that it was not published in a journal that is more widely available in the medical community.
43. Tarr PI, Neill MA: Perspective: The problem of non-O157:H7 Shiga toxin (verocytotoxin) - producing Escherichia coli. J Infect Dis 1996, 174:1136-1139. This commentary briefly reviews non-O157:H7 enterohemorrhagic E. coli but more importantly, presents thoughtful guidance to clinicians on the diagnosis and significance of these serotypes in clinical specimens.
44. Samadpour M, Ongerth JE, Liston J, Tran N, Nguyen D, Whittam TS, Wilson RA, Tarr PI: Occurrence of Shiga-like toxin-producing Escherichia coli in retail fresh seafood, beef, lamb, pork, and poultry from grocery stores in Seattle, Washington. Appl Environ Microbiol 1994, 60:1038-1040.
45. Watanabe H, Wada A, Inagaki Y, Itoh K, Tamura K: Outbreak of enterohaemorrhagic Escherichia coli O157:H7 infection in two different genotype strains in Japan, 1996. Lancet 1996, 348:831-832.
46. Bender JB, Hedberg CW, Besser JM, Boxrud DJ, Macdonald KL, Osterholm MT: Surveillance for Escherichia coli O157:H7 infections in Minnesota by molecular subtyping. N Engl J Med 1997, 337:388-394. This article describes the use of pulsed-field gel electrophoresis as a molecular-subtyping system to discriminate various strains of E. coli O157:H7 submitted to the Minnesota Department of Health. This method detected four outbreaks that were not detected by traditional methods and also established that sudden increases in reported cases were more commonly due to sporadic isolated cases rather than outbreaks.
47. Michino H, Araki K, Minami S, Takaya S, Sakai N: Investigation of large-scale outbreak of Escherichia coli O157:H7 infection among schoolchildren in Sakai City, 1996. In Abstracts of the 32nd Joint US-Japan Cooperative Medical Science Program Cholera and Related Diarrhea! Diseases Panel: 1996 Nov; Nagasaki, Japan.
48. Centers for Disease Control: Outbreaks of Escherichia coli O157:1-17 infection associated with eating alfalfa sprouts -Michigan and Virginia, June-July 1997. Morbid Mortal Weekly Rep 1997, 46:741-744.
49. Wallace JS, Cheasty T, Jones K: Isolation of vero cytotoxin-producing Escherichia coli O157 from wild birds. J Appl Microbiol 1997, 82:399-404.
50. Tarr PI, Fouser LS, Stapleton AE, Wilson RA, Kim HH, Vary JC Jr, Clausen CR: Hemolytic-uremic syndrome in a six-year-old girl after a urinary tract infection with Shiga-toxin-producing Escherichia coli O103:H2. N Engl J Med 1996, 335:635-637.
51. Djafari S, Ebel F, Deibel C, Krämer S, Hudel M, Chakraborty T: Characterization of an exported protease from Shiga toxin-producing Escherichia coli. Mol Microbiol 1997, 25:771-784.